Type 1 plasminogen activator inhibitor (PAI-1) is the primary inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Whereas PAI-1 is not expressed in normal kidneys, it is strongly induced in glomerular diseases and thus could promote the local accumulation of fibrin. To study the role of PAI-1 in the development of inflammatory glomerular injury, passive antiglomerular basement membrane (GBM) glomerulonephritis (GN) was induced in PAI-1 knockout mice and in wild-type mice of the same genetic background. Unexpectedly, PAI-1 deficiency was associated with an early and severe exacerbation of glomerular injury: Infiltration by CD 4 T cells, proportion of fibrinous crescents, and renal function impairment were significantly more pronounced in PAI-1 -/-mice. Interestingly, activation of transforming growth factor (TGF)-β, which is known to be dependent on the PA/plasmin system in vitro, was dramatically enhanced in the kidneys in the absence of PAI-1. Moreover, administration of neutralizing antibodies against TGF-β significantly attenuated the disease in PAI-1 -/-mice. This suggests that the poor outcome of GN in PAI-1 -/-mice is consecutive to an uncontrolled activation of TGF-β and confers PAI-1 with a new, immunomodulatory role.
catalyze the conversion of plasminogen to plasmin, a key and broad-spectrum enzyme responsible for fibrinolysis, extracellular matrix breakdown, and activation of growth factors (3) . It has been documented that plasminogen or tPA deficiency aggravates the course of experimental crescentic glomerulonephritis and that administration of recombinant tPA exerts a protective effect on the course of the experimental disease (4, 5) . Both PAs are inhibited by type 1 plasminogen activator inhibitor (PAI-1). Although PAI-1 is not produced by the normal kidney, its local synthesis has been found to be enhanced during a number of pathological renal processes, including in humans (6) (7) (8) . So far, this de novo PAI-1 synthesis is supposed to play a deleterious role by preventing the fibrinolytic and proteolytic action of plasmin, thereby promoting the persistence of fibrin and the evolution toward renal fibrosis (9, 10) . In the present study, we explored the pathogenic role of PAI-1 in the passive model of anti-glomerular basement membrane glomerulonephritis in mice genetically deficient in PAI-1. Our results demonstrate that PAI-1 paradoxically serves a protective role during the course of glomerulonephritis.
MATERIALS AND METHODS

Genetically modified mice
The experiments were performed on PAI-1 -/-and +/+ female mice, with an identical genetic background (87.5% C57BL/6, 12.5% 129SvJ), generated by P. Carmeliet (Center for Transgene Technology and Gene Therapy, Leuven, Belgium) (11) . Genotyping was performed by PCR amplification of genomic DNA extracted from tail samples by proteinase K digestion, with primers designed to anneal to the neomycin resistance gene or to the PAI-1 native gene. There were six mice or more in each group for each experiment. The animals were maintained with a 12 h light/12 h dark cycle and had free access to food and water. Mouse studies followed the institutional animal care and use guidelines.
Antibodies and reagents
Sheep anti-rat GBM serum was supplied by B. Fouqueray (Institut National de la Santé et de la Recherche Médicale U489, Paris, France) and was shown to induce crescentic glomerulonephritis in mice (12, 13) . Immunofluorescence studies were performed with FITCconjugated rabbit anti-sheep IgGs antibodies (Vector Laboratories, Burlingame, CA), FITCconjugated rabbit anti-Mouse IgGs antibodies (Jackson Immunoresearch Laboratory, West Grove, PA), F4/80 hybridomas provided by R. Monteiro (Institut National de la Santé et de la Recherche Médicale U25, Paris, France), FITC-conjugated rat anti-mouse CD 4 antibodies (PharMingen, San Diego, CA), and FITC-conjugated goat anti-mouse fibrinogen (Nordic Immunological Laboratories, Tilburg, The Netherlands). Recombinant human latent transforming growth factor (TGF)-β was purchased from R&D Systems (Minneapolis, MN). Human uPA was purchased from Sanofi Synthelabo (France) and tPA from Biopool (Ventura, CA). Human plasmin was purchased from Sigma (St. Louis, MO).
Induction of passive glomerulonephritis
For induction of glomerulonephritis, 2-month-old female mice were i.v. injected in the caudal vein with 200 µl of sheep anti-GBM serum. They were studied 7, 14, and 28 days after injection.
Northern blot analysis
Total kidney RNA was isolated using the TRIZOL single-step reagent (Invitrogen, Carlsbad, CA). RNA samples (20 µg) from each individual animal were separated by electrophoresis through 0.9% agarose gels and transferred to nylon membranes (GeneScreen Plus; New England Nuclear Life Science Product, Boston, MA). Nucleic acids were immobilized by UV irradiation. The membranes were hybridized at 65°C for 16 h in UltraHyb hybridization solution (Ambion, Austin, TX) containing DNA probes labeled with α 32 P dCTP by random oligonucleotide priming (Boehringer Mannheim Biochemicals, Indianapolis, IN) and exposed to autoradiographs. The density of each band was quantified using the NIH (Bethesda, MD) image program. The results were adjusted for unequal RNA loading based on the intensity of the RNA band for a housekeeping gene (mouse GAPDH). Results were expressed in arbitrary densitometric units (AU). The c-DNA probes used were mouse PAI-1 cDNA from D. Loskutoff (The Scripps Research Institute, La Jolla, CA), and mouse α 2-antiplasmin cDNA generated by PCR, using the following primers: sense 5′-AATTGTTCCAGGGCCCAGACCTTCGT-3′; antisense: 5′GTCCTCCATGATGAAAAGAGGAAGGG-3′. Northern Blot analyses were performed at day 7 after induction of glomerulonephritis.
Assessment of renal function and proteinuria
Mice were housed individually in metabolic cages to collect urine over 24 h. During this time, they were supplied with food and tap water ad libitum. Serum and urine creatinine (alkaline picric acid method) and urine total proteins (Biuret method) were measured on an autoanalyzer (Instrumentation Laboratory).
Histological assessment of glomerular and tubular injury
Renal tissue was fixed in Dubosq-Brazil's fixative, embedded in paraffin, cut into 3-µm sections, and stained with periodic acid-Schiff stain and Masson's Trichrome for histological analysis. Crescent formation (defined as the presence of two or more layers of cells in Bowman's space) and fibrin deposition were determined on 50 glomeruli per section. Tubular lesions were assessed by a morphometric method using intercepts. For each case, microphotographs (magnification 400×) at five randomly selected fields were digitalized and displayed using Photoshop Software (Version 5.5, Adobe System). A tracing paper was used to count, among 33 intercepts, normal or injured tubules. Tubular lesion index (TLI) was calculated as the ratio injured tubules/normal tubules.
Immunofluorescence studies
GBM deposits of injected sheep anti-GBM antibody or of mouse IgGs directed against injected sheep antibody were assessed by immunofluorescence on 3-µm kidney cryosections fixed in 4% paraformaldehyde (diluted in phosphate-buffered saline 1×, pH 7.4). Binding was detected after a 30-min incubation with species-specific FITC-conjugated anti-sheep or anti-mouse IgG diluted 1:200.
For detection of CD 4 + T cells and macrophages, 3-µm cryosections fixed in 4% paraformaldehyde were incubated for 1 h with FITC-conjugated rat anti-mouse CD 4 diluted 1:25 and F4/80 hybridomas diluted 1:2, respectively. The number of macrophages and CD 4 + T cells was determined on 30 glomeruli per kidney and expressed as the number of cells per glomerulus.
Fibrin deposition was detected by immunofluorescence on cryosections fixed in 4% paraformaldehyde for 10 min at room temperature and incubated for 30 min with FITCconjugated goat anti-mouse fibrin diluted 1:50. Glomerular fibrin deposition was assessed using a semiquantitative protocol (14) . A minimum of 30 glomeruli were scored (0 to +3) to determine a mean score for each animal. Glomeruli for which fluorescence was not different from background were scored 0, glomeruli with sparse fibrin deposition in the glomerular tuft were scored +1, glomeruli with prominent fibrin deposition in the glomerular tuft were scored +2, and glomeruli with prominent fibrin deposition in both the glomerular tuft and in Bowman's space were scored +3. Histological and immunofluorescence analysis were performed by two independent examiners (A.H. and Y.A.) unaware of the genotypes of the mice.
Antibody response
Circulating mouse IgGs directed against injected sheep anti-GBM antibody were measured in the sera by ELISA as described previously (15) . In brief, Costar 96-well plates were coated overnight with 1 µg/well of sheep IgG (Sigma), washed, and blocked with 2% bovine serum albumin. Then, wells were incubated for 3 h with dilutions of mouse serum followed by speciesspecific rabbit anti-mouse IgG conjugated to peroxydase for 2 h at a dilution of 1:2000. Peroxydase was revealed by O-phenylenediamine, and absorbance was read at 450 nm on a Titertek Multiskan MCC/340 (Lab-system Group). Serum from each mouse was tested in serial dilutions from 1:25 to 1:1000 with serum from five noninjected mice used as negative controls.
Thrombin /antithrombin III (TAT) determinations
Half-kidneys were homogenized in 1 ml of PBS, the homogenate was centrifuged at 4000g for 10 min at 4°, and the supernatant stored at -80°C. TAT complex concentrations were determined by an ELISA kit designed for human TAT (Enzygnost TAT; Dade-Behring, Liederbach, Germany), which also cross-reacts with murine TAT (16) . The content of murine TAT was calculated according to the human TAT standard curve.
Detection of plasminogen activators by fibrin zymography
Whole protein extracts (150 µg/well) were separated on a 10% SDS-polyacrylamide gel. Plasminogen activators activity was detected on a fibrin agar underlay (fibrinogen 10 mg/ml, thrombin 300 mU/ml, agarose 1%) containing plasminogen (20 µg/ml) as described previously (17) . The gels were incubated at 37°C in a humidified atmosphere to reveal lysis zones corresponding to the presence of plasminogen activators activity. PA-specific bands were verified by their disappearance in the presence of aprotinin. Molecular weight markers, human urokinase (1 U/ml) and t-PA (2 U/ml), were loaded into the outer wells to confirm the correct sizes of PAs.
Plasmin activity of kidney homogenates
The plasmin activity of kidney homogenates was measured by chromogenic substrate assay. In brief, 150 µg of total kidney proteins were placed in 100 µl PBS and 20 µl of a 3 mmol/l plasmin-specific substrate solution (H-D-Val-Leu-Lys-p-nitroaniline dihydrochloride; S-2251, Chromogenix, Italy), and 100 µl of 100 mmol/l Tris-HCl buffer (pH 8.0) were added. After 4 h of incubation at room temperature, the amount of p-nitroaniline released was measured at 405 nm with a microplate reader. Standard curves were generated using human plasmin (Sigma). Plasmin activity was expressed as U/µg protein.
TGF-β measurement
Active TGF-β 1 levels were determined by an ELISA assay (Quantikine, R&D Systems) on whole protein extracts isolated from half-kidneys homogenized in 1 ml of 50 mM Tris HCl, 110 mM NaCl, 10 mM EDTA, and 0.1% Triton X-100. The homogenate was centrifuged at 14,000g for 10 min at 4°C, and the supernatant was collected. Active TGF-β1 levels were determined immediately without acid treatment of samples. Total (active plus latent) TGF-β1 levels were determined after acid activation of samples. In separate in vitro experiments, recombinant human latent TGF-β was incubated for 2 h at 37°C alone and in the presence of increasing concentrations of each plasminogen activator to explore their capacity to convert latent TGF-β into active TGF-β (in three independent experiments). Acid-and/or plasmin-activated latent TGF-β were used as positive controls.
Tranexamic acid treatment
To block the lysin binding site in plasminogen and plasmin, we administered tranexamic acid by daily s.c. injections (1.8 mg/day) and added it to the drinking water at 20 mg/ml.
TGF-β neutralization
Neutralization of TGF-β was achieved by i.v. injection in the tail of a dose of 150 µg of polyclonal rabbit anti-pan TGF-β antibodies (Sigma), at day 1 and 7, as described previously (18) . Control animals were injected with rabbit control IgG (Sigma).
Statistical analysis
Values are expressed as mean ±SE. Differences between PAI-1 +/+ and PAI-1 -/-mice were analyzed using Mann-Whitney U test. P<0.05 was considered statistically significant.
RESULTS
Glomerulonephritis induces PAI-1 mRNA synthesis in the kidneys of wild-type mice
Whereas PAI-1 is poorly expressed in normal kidneys, Northern Blot analysis of RNAs extracted from total kidneys disclosed a clear induction of PAI-1 mRNA synthesis in PAI-1 +/+ mice 4 h after an i.p. injection of 100 µg lipopolysaccharide (used as a positive control) and at day 7 after injection of nephrotoxic serum. This induction was not observed in PAI-1 -/-mice (Fig. 1) . By contrast, we found the same level of expression of α2-antiplasmin mRNA level in control mice and in mice with GN, in both genotypes [PAI-1 +/+ mice with GN: 5.2±0.3 AU (n=5) vs. 5.9 (n=1) in control mouse; PAI-1 -/-mice with GN: 6.4±0.4 AU (n=5) vs. 6.5 (n=1) in control mouse].
PAI-1 deficiency decreases renal function and increases proteinuria and mortality in mice with anti-GBM glomerulonephritis
Baseline values of proteinuria were comparable in PAI-1 +/+ and PAI-1 -/-mice (PAI-1 +/+ mice: 1.36±0.5 g/mmol creatinine; PAI-1 -/-mice: 1.55±0.4 g/mmol creatinine). Injection of nephrotoxic serum induced a sharp increase in daily proteinuria in both strains, but to a higher extent in PAI-1 -/-mice, at each time experiment, from day 7 to day 28 ( Fig. 2A) . Whereas the evolution of daily proteinuria showed a trend toward the improvement, the difference in proteinuria levels between days 14 and 28 did not reach statistical significance in PAI-1 -/-or in PAI-1 +/+ mice.
Similarly, both genotypes developed renal failure, but serum creatinine at day 28 was significantly higher in PAI-1 -/-mice (Fig. 2B) . Notably, when the mice were killed, we observed that most PAI-1-deficient mice had macroscopically abnormal kidneys, red-brown in color, with a granular surface, and that ascite was a common finding. We did not observe such macroscopical lesions in lung, heart, or liver.
In a separate experiment, when a cohort of 10 mice in each group was prospectively followed on a long-term period, PAI-1 -/-mice showed a dramatic increase in mortality when compared with PAI-1 +/+ mice (Fig. 3) . The high degree of renal impairment, assessed by the value of serum creatinine, that we oberved in PAI-1 -/-mice in this model, together with the absence of macroscopical lesions in other organs, makes us feel confident that PAI-1 deficient animals did die of renal failure.
PAI-1 deficiency aggravates histological features of glomerulonephritis
We observed a significant difference in histological features of GN between both genotypes. Although both PAI-1 -/-and PAI-1 +/+ mice developed fibrinous and crescentic glomerulonephritis, disease was surprisingly more severe in PAI-1 -/-mice (Fig. 4, 5 ): Their incidence of fibrin-positive crescents was significantly increased (50.9% ± 4.8 in PAI-1 -/-mice vs. 27.6% ± 5.5 in PAI-1 +/+ mice, P<0.01). Immunofluorescence studies with FITC-conjugated anti-mouse fibrin antibody confirmed that the mean glomerular score for fibrin deposits was significantly higher in PAI-1 -/-mice (Fig. 4, 5) . Tubular lesions were also more pronounced in the group of PAI-1 -/-mice, yet the difference was not statistically significant (TLI=0.31 ± 0.12 in PAI-1 -/-mice vs. 0.19 ± 0.08 in PAI-1 +/+ mice, P=0.14).
Immunofluorescence studies of immunoglobulin deposits and inflammatory infiltrates
Most glomeruli from both genotypes showed positive staining for sheep IgGs and for mouse IgGs along the glomerular basement membrane at day 28 ( Fig. 6) , disclosing a similar humoral response toward sheep IgGs. This was further confirmed by the measurement of circulating levels of mouse anti-sheep IgG antibodies at day 28, which were identical in both groups (data not shown).
Glomeruli from both genotypes disclosed leukocyte accumulation in the vicinity of injured glomeruli, with both CD 4 + T cell and macrophage infiltrates (Fig. 6 ). Infiltration by CD 4 + T cells was markedly increased in PAI-1 -/-mice when compared with PAI-1 +/+ mice (2.05±0.35 and 0.73±0.27 CD 4 + cells/glom, respectively, P<0.01; Fig. 5 ), suggesting that PAI-1 deficiency leads to enhanced glomerular lesions through a facilitated CD 4 + T cell response. The glomerular score of macrophage infiltration was similar between both genotypes (0.73±0.22 macrophages/glom vs. 0.77±0.22 macrophages/glom in the PAI-1 -/-and PAI-1 +/+ mice, respectively, P=1; Fig.  5 ).
Intrarenal coagulation is enhanced in PAI-1-deficient mice
To reconcile the apparent paradox that PAI-1-deficient animals have a poorer outcome and more fibrin deposition despite a theoretically enhanced fibrinolytic activity, we explored the possibility that the rate of fibrin formation could exceed its clearance in the context of PAI-1 deficiency. Because thrombin is critically involved in crescentic glomerulonephritis, through its procoagulant, and proinflammatory properties mediated by its specific receptor PAR1 (14), we hypothesized that PAI-1-deficient mice presented a more severe glomerulonephritis because of an enhanced thrombin production. In agreement with this, TAT complex concentrations were found to be higher in PAI-1 -/-mice than in PAI-1 +/+ mice during anti-GBM glomerulonephritis (1.71±0.4 µg/mg prot in PAI-1 -/-mice vs. 0.66±0.15 µg/mg prot in PAI-1 +/+ mice, P<0.05). TAT complexes were undetectable in renal tissue in mice from both genotypes without GN.
Renal PAs activity-but not plasmin activity-is enhanced in PAI-1-deficient mice
The activity of plasminogen activators was explored by fibrin zymography. As shown in Figure  7 , glomerulonephritis induced a decrease in uPA-related fibrinolysis in wild-type animals compared with control mice, and a modest increase in tPA-related fibrinolysis. By contrast, lack of PAI-1 resulted in a large increase in both uPA-and tPA-related fibrinolysis. However, intrarenal plasmin activity was found to be similar during GN in both genotypes (10.6±2.6 U/µg prot vs. 13.23±3.2 U/µg prot in PAI-1 +/+ and PAI-1 -/-mice, respectively, P=0,82).
To further determine whether PAI-1 deficiency exacerbates glomerular injury through plasminor PA-dependent effects, we tried to diminish the severity of the disease with tranexamic acid, a potent inhibitor of plasmin activity and of plasmin generation. This treatment induced an early increase in the mortality (66% of PAI-1 -/-mice at day 7) and considerably enhanced the glomerular deposition of fibrin in both strains (data not shown).
TGF-β plays a critical role in the severity of GN in PAI-1-deficient mice
Crescentic glomerulonephritis is a Th1-mediated disease (19) . Based on the observation that CD 4 + T cell infiltration is greater in the kidneys of PAI-1 -/-mice, combined with an increased thrombin production and an early enhancement of proteinuria compared with wild-type mice, we sought to determine the mechanisms by which PAI-1 deficiency could potentiate T cell response to heterologous anti-GBM serum. Among its biological substrates, the PA/plasmin system is known to activate the latent form of TGF-β, a multifunctional cytokine that was recently shown to be involved in the development of crescentic anti-GBM glomerulonephritis (20) . Active TGF-β 1 level was dramatically higher in PAI-1 -/-mice during GN (199.2±71.9 pg/mg protein in PAI-1 -/-mice vs. 10.9±5.9 pg/mg protein in PAI-1 +/+ mice, P=0.01; Table 1 ). Because plasminogen activators-but not plasmin-activity was enhanced in PAI-1-deficient mice, we sought to determine whether plasminogen activators could activate latent TGF-β independently from plasmin. As shown in Figure 8 , we observed that, in vitro, human uPA and tPA were capable of activating human latent TGF-β, in a dose-dependent manner, in the absence of plasminogen and of plasmin. This biological effect was abolished by aprotinin, a nonspecific serine protease inhibitor, but not by tranexamic acid (data not shown).
Finally, in vivo neutralization of TGF-β by specific antibodies in PAI-1 -/-mice induced a significant reduction of proteinuria when compared with PAI-1 -/-animals injected with rabbit control IgGs, at both day 14 and 28 after induction (Fig. 9) . Histological analysis showed a significant reduction in the proportion of fibrin-positive crescents (18.4±4.2% in mice treated with anti-TGF-β antibodies vs. 36.4±6.5% in mice treated with control IgGs, P<0.05; Fig. 8 ). By an immunofluorescence study, we also observed a significant reduction of the CD 4 + T cells (1.29±0.16 cell/gl in the group treated with control rabbit IgG vs. 0.54±0.20 cell/gl in the group treated with anti-TGF-β antibodies, P<0.05). This protective effect was not observed in PAI-1 +/+ mice: Proteinuria was unchanged at days 7, 14, and 28; the proportion of fibrin-positive crescents was also identical between both groups (12.8±1.9% in wild-type mice treated with nonspecific rabbit IgGs vs. 13.2±1.2% in wild-type mice treated with anti-TGF-β antibodies, P=0.94). In both groups treated with anti-TGF-β antibodies, a reduction of the intrarenal concentration of active TGF-β was observed when compared with the groups treated with nonspecific antibodies, but this difference reached a statistical significance in PAI-1 -/-mice only (Table 2 ).
DISCUSSION
Our findings show that PAI-1 deficiency drastically exacerbates the course of passive, immunemediated, crescentic glomerulonephritis. The absence of PAI-1 resulted in greater histological and functional damage and in a higher intrarenal concentration of thrombin, a key mediator of the disease. PAI-1 -/-mice were also found to have a superior induction of the synthesis and of the activation of TGF-β, most likely related to enhanced plasminogen activator activity. Moreover, systemic neutralization of TGF-β significantly attenuated the severity of their disease.
Several arguments indicate that all these findings were related to increased PA activity, rather than to increased plasmin activity: a) We found that the intrarenal activity of plasmin was not enhanced in the absence of PAI-1 during glomerulonephritis; b) there is substantial evidence in the literature that plasmin has a protective effect during anti-GBM glomerulonephritis, as attested by the enhanced severity of disease in plasminogen-deficient mice (21); c) accordingly, we found, in both genotypes, that tranexamic acid aggravates the course of the disease; and d) α2-antiplasmin, but not PAI-1, seems to be the main regulator of fibrinolysis in the kidneys after endotoxin injection (22) . In addition, in our model, the persistent expression of α2-antiplasmin seems sufficient to blunt the enhanced generation of plasmin resulting from the increased PA activity in PAI-1-deficient mice. Taken together, this suggests that the increased activity of PA observed in the absence of PAI-1 worsens the course of glomerulonephritis independently from their role in the generation of plasmin, because of their proper enzymatic action.
The PA/plasmin system has other biological substrates besides fibrin and matrix proteins, and among them growth factors, including TGF-β (23, 24) . This plasmin-or PA-dependent activation of TGF-β was found to be relevant in vitro and in vivo (25, 26) . Interestingly, we demonstrated in our model that the absence of PAI-1 leads to a much higher activation of TGF-β than in wild-type mice and that in vivo neutralization of TGF-β induces a significant decrease in proteinuria and in crescentic lesions in PAI-1 -/-mice. Recently, in a model of accelerated atherosclerosis, Luttun et al. found that vascular fibrosis was facilitated in PAI-1-deficient mice (27) . The amount of active TGF-β in PAI-1-deficient animals was strikingly higher in the aortic vasculature than in PAI-1 +/+ animals, and profibrotic effects of this cytokine on a long-term period could indeed account for this tissue and model-dependent vascular fibrosis. Similarly, it is likely that an enhanced activation of TGF-β is deleterious during crescentic anti-GBM glomerulonephritis. Kanamaru et al. generated transgenic mice expressing inhibitory Smad7, an intracellular antagonist of TGF-β/Smad signaling, under the control of a distal lck promoter that directed high expression in peripheral T cells (20) . When inducing antibody-mediated glomerulonephritis, they observed that glomerulonephritis was suppressed in these mice, which had a marked reduction in the infiltration of CD 4 + T cell into glomeruli.
Interestingly, we observed that plasminogen activators do have the capacity to activate latent TGF-β in vitro, in the absence of plasmin. Altogether, our findings suggest that PAI-1 deficiency induces a PA-related overactivation of TGF-β, which may amplify the T cell-mediated immune glomerular injury in the anti-GBM model. The greater CD 4 + T cell infiltration observed in the vicinity of glomeruli from PAI-1 -/-mice, as well as its reduction after administration of antibodies against TGF-β, further supports this scenario. In contrast, in wild-type mice, the amount of active TGF-β is limited, especially when PAI-1 is induced at the early phase of the disease. This may explain the lack of a significant effect of anti-TGF-β antibodies in PAI-1 +/+ mice.
The respective roles of tPA and uPA in the deleterious overactivation of TGF-β in PAI-1-deficient mice remain unknown. However, tPA deficiency has been reported to worsen the severity of anti-GBM glomerulonephritis in mice, and infusion of recombinant tPA at the early phase of the disease has been shown to improve the outcome of the disease in terms of glomerular fibrin and matrix deposition, without enhancing TGF-β activation (4, 28) . Therefore, the poor outcome of PAI-1-deficient mice in our model is more probably related to the excessive activity of uPA rather than that of tPA.
We applied the passive model of anti-GBM glomerulonephritis to mice with a congenic genetic background (87.5% C57Bl/6; 12.5% 129 SvJ). Actually, contradictory data have been reported in the literature concerning the impact of PAI-1 gene deficiency toward organ fibrogenesis, which might be explained by differences in the genetic background of the animals. Several studies, using mice that had been backcrossed to C57BL/6, demonstrated that PAI-1 null mice were protected against fibrosis (29) (30) (31) (32) . In contrast, another study, using mice with the same congenic background than the one we used, found that PAI-1 deficiency was facilitating vascular fibrosis (27) . Thus, we may not exclude the role of modifier genes in our results. One exception is from the study by Oda et al., in which PAI-1-deficient mice with a congenic genetic background were found to be protected against renal fibrosis following unilateral ureteral obstruction (33) . Yet, interestingly, in the study by Oda et al., the mechanism by which PAI-1 deficiency was protective, is not obvious, because the plasmin activity in PAI-1-deficient kidneys was found to be unaltered and because recently, in the same model, tPA deficiency was also found to serve a protective role (34) . This further illustrates the complexity of the PA/plasmin system in vivo and the influence of the model and/or of the organ studied.
Here, we demonstrate that PAI-1 gene suppression is deleterious in the passive model of crescentic glomerulonephritis, a yet fibrin-dependent disease, by leaving TGF-β activation uncontrolled, thereby potentiating the immune response in the peri-glomerular environment. This confers PAI-1 with a new, original immunomodulatory role.
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